Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study

Fig. 2

Cumulative incidence of worsening T2DM control in T2DM men by PCa status in PCa + GnRH exposure cohort a. Figure 2. In this figure, we found that, in the PCa + GnRH exposure cohort, men receiving GnRH had a higher cumulative incidence for worsening diabetes control, compared with PCa free men. The changes in the HbA1c measurements (Fig. 2-(a), Fig. 2-(b)) occurred earlier and more obviously than the addition of new antidiabetic medications (Fig. 2-(c)). When we combined the criteria to identify the event in Fig. 2-(a), Fig. 2-(b) and Fig. 2-(c) to create the combination event, we found that cumulative incidence of combination event is higher in PCa men with GnRH compared with men without PCa (Fig. 2-(d)). In Fig. 2-(a), we excluded men with a HbA1c over 58 mmol/l and men without HbA1c data at baseline. In Fig. 2-(b), men without HbA1c data at baseline were excluded. Men using insulin and men without antidiabetic drugs at the baseline were excluded in Fig. 2-(c)

Back to article page